Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
Aileron Therapeutics Reports Positive Phase 1b Data Of LTI-03 In Idiopathic Pulmonary Fibrosis
(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).
Yahoo Finance1d
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Ph.D., President and Chief Executive Officer of Aileron. "Additionally, we saw dose dependent effects in five biomarkers ...
Aileron reports results from Cohort 2 of its Phase 1b clinical trial of LTI-03
Aileron Therapeutics (ALRN) announced positive topline data from Cohort 2 of its Phase 1b clinical trial evaluating the safety and tolerability ...
Morningstar7d
Aileron Therapeutics Inc ALRN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Investing14d
Advancium explores ALRN-6924 for pediatric eye cancer treatment
AUSTIN, Texas and NEW YORK - Aileron Therapeutics, Inc. (NASDAQ: NASDAQ:ALRN), a biopharmaceutical company, and Advancium Health Network, a public charity, have announced an exclusive option agreement ...
who1314d
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
AUSTIN, Texas and NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to ...